150 related articles for article (PubMed ID: 21278560)
21. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
22. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
Nakanishi T; Aoki D; Watanabe Y; Ando Y; Tomotsugu N; Sato Y; Saito T
Jpn J Clin Oncol; 2015 May; 45(5):422-6. PubMed ID: 25670764
[TBL] [Abstract][Full Text] [Related]
23. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Moskowitz AJ; Shah G; Schöder H; Ganesan N; Drill E; Hancock H; Davey T; Perez L; Ryu S; Sohail S; Santarosa A; Galasso N; Neuman R; Liotta B; Blouin W; Kumar A; Lahoud O; Batlevi CL; Hamlin P; Straus DJ; Rodriguez-Rivera I; Owens C; Caron P; Intlekofer AM; Hamilton A; Horwitz SM; Falchi L; Joffe E; Johnson W; Lee C; Palomba ML; Noy A; Matasar MJ; Pongas G; Salles G; Vardhana S; Sanin BW; von Keudell G; Yahalom J; Dogan A; Zelenetz AD; Moskowitz CH
J Clin Oncol; 2021 Oct; 39(28):3109-3117. PubMed ID: 34170745
[TBL] [Abstract][Full Text] [Related]
24. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
[TBL] [Abstract][Full Text] [Related]
25. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age.
Addeo R; Faiola V; Guarrasi R; Montella L; Vincenzi B; Capasso E; Cennamo G; Rotundo MS; Tagliaferri P; Caraglia M; Del Prete S
Cancer Chemother Pharmacol; 2008 Jul; 62(2):285-92. PubMed ID: 17922275
[TBL] [Abstract][Full Text] [Related]
26. Pegylated liposomal doxorubicin (Duomeisu
Jiang H; Li H; Song G; Di L; Shao B; Yan Y; Liu X; Chen Y; Zhang R; Ran R; Liu Y; Gui X; Wang N; Wang H
Breast Cancer Res Treat; 2023 May; 199(1):67-79. PubMed ID: 36877215
[TBL] [Abstract][Full Text] [Related]
27. Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study.
Petru E; Angleitner-Boubenizek L; Reinthaller A; Deibl M; Zeimet AG; Volgger B; Stempfl A; Marth C
Gynecol Oncol; 2006 Aug; 102(2):226-9. PubMed ID: 16443259
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and toxicity of gemcitabine and pegylated liposomal Doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancer.
Karaoglu A; Arslan UY; Ozkan M; Kalender ME; Alici S; Coskun U; Gumus M; Celenkoglu G; Er O; Sevinc A; Buyukberber S; Alkis N; Benekli M;
Asian Pac J Cancer Prev; 2009; 10(1):63-6. PubMed ID: 19469626
[TBL] [Abstract][Full Text] [Related]
29. Gemcitabine plus doxorubicin as first-line treatment in advanced or metastatic breast cancer (MBC), a phase II study.
El Serafi MM; El Khodary AI; El Zawahry HR; Mansour OM; Gaballa HE
J Egypt Natl Canc Inst; 2006 Sep; 18(3):209-15. PubMed ID: 17671530
[TBL] [Abstract][Full Text] [Related]
30. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
Park JS; Jeung HC; Rha SY; Ahn JB; Kang B; Chon HJ; Hong MH; Lim S; Yang WI; Nam CM; Chung HC
Cancer Chemother Pharmacol; 2014 Oct; 74(4):799-808. PubMed ID: 25107569
[TBL] [Abstract][Full Text] [Related]
31. Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer.
Chang AE; Wu QV; Jenkins IC; Specht JM; Gadi VK; Gralow JR; Salazar LG; Kurland BF; Linden HM
Clin Breast Cancer; 2018 Feb; 18(1):e143-e149. PubMed ID: 29174203
[TBL] [Abstract][Full Text] [Related]
32. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study.
Martín M; Sánchez-Rovira P; Muñoz M; Baena-Cañada JM; Mel JR; Margeli M; Ramos M; Martínez E; García-Saenz JA; Casado A; Jaén AM; González-Farré X; Escudero MJ; Rodriguez-Martin C; Carrasco E;
Ann Oncol; 2011 Dec; 22(12):2591-2596. PubMed ID: 21421542
[TBL] [Abstract][Full Text] [Related]
33. Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study.
Lombardi G; Zustovich F; Farinati F; Cillo U; Vitale A; Zanus G; Donach M; Farina M; Zovato S; Pastorelli D
Cancer; 2011 Jan; 117(1):125-33. PubMed ID: 21058409
[TBL] [Abstract][Full Text] [Related]
34. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
[TBL] [Abstract][Full Text] [Related]
35. Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.
Schmid P; Krocker J; Schulz CO; Michniewicz K; Dieing A; Eggemann H; Heilmann V; Blohmer JU; Sezer O; Elling D; Possinger K
Anticancer Drugs; 2005 Jan; 16(1):21-9. PubMed ID: 15613900
[TBL] [Abstract][Full Text] [Related]
36. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies.
Fracasso PM; Blum KA; Tan BR; Fears CL; Bartlett NL; Arquette MA; Clark RS
Cancer; 2002 Nov; 95(10):2223-9. PubMed ID: 12412177
[TBL] [Abstract][Full Text] [Related]
38. Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group.
Fountzilas G; Papakostas P; Dafni U; Makatsoris T; Karina M; Kalogera-Fountzila A; Maniadakis N; Aravantinos G; Syrigos K; Bamias A; Christodoulou C; Economopoulos T; Kalofonos H; Nikolaou A; Angouridakis N; Stathopoulos G; Bafaloukos D; Pavlidis N; Daniilidis J
Ann Oncol; 2006 Oct; 17(10):1560-7. PubMed ID: 16790517
[TBL] [Abstract][Full Text] [Related]
39. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.
Mlineritsch B; Schabel-Moser R; Andel J; Fridrik M; Moik M; Mayer P; Russ G; Rass C; Greil R;
Onkologie; 2009 Feb; 32(1-2):18-24. PubMed ID: 19209014
[TBL] [Abstract][Full Text] [Related]
40. Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study.
Crespo G; Sierra M; Losa R; Berros JP; Villanueva N; Fra J; Fonseca PJ; Luque M; Fernández Y; Blay P; Sanmamed M; Muriel C; Esteban E; Lacave AJ
Int J Gynecol Cancer; 2011 Apr; 21(3):478-85. PubMed ID: 21436695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
